These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 35840917)
21. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N; Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337 [TBL] [Abstract][Full Text] [Related]
22. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Yamada Y; Boku N; Mizusawa J; Iwasa S; Kadowaki S; Nakayama N; Azuma M; Sakamoto T; Shitara K; Tamura T; Chin K; Hata H; Nakamori M; Hara H; Yasui H; Katayama H; Fukuda H; Yoshikawa T; Sasako M; Terashima M Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):501-510. PubMed ID: 31101534 [TBL] [Abstract][Full Text] [Related]
23. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332 [TBL] [Abstract][Full Text] [Related]
24. A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. Nishikawa K; Murotani K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Hasegawa H; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T Cancer Chemother Pharmacol; 2019 May; 83(5):867-874. PubMed ID: 30806758 [TBL] [Abstract][Full Text] [Related]
25. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648 [TBL] [Abstract][Full Text] [Related]
26. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323 [TBL] [Abstract][Full Text] [Related]
27. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659 [TBL] [Abstract][Full Text] [Related]
28. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. Mitani S; Kadowaki S; Hasegawa H; Wakatsuki T; Hara H; Tajika M; Nishikawa K; Hirao M; Takahari D; Chin K; Muro K Int J Clin Oncol; 2019 Oct; 24(10):1197-1203. PubMed ID: 31152323 [TBL] [Abstract][Full Text] [Related]
29. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial. Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825 [TBL] [Abstract][Full Text] [Related]
30. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T; Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688 [TBL] [Abstract][Full Text] [Related]
31. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA; Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072 [TBL] [Abstract][Full Text] [Related]
32. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T; Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053 [TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938 [TBL] [Abstract][Full Text] [Related]
34. SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Boisteau E; François E; Aparicio T; Le Malicot K; Boulahssass R; Lecomte T; Laurent-Puig P; Guiu B; Paillaud E; Galais MP; Lopez-Trabada Ataz D; Tougeron D; Dourthe LM; Guimbaud R; Samalin E; Moreau M; Louvet C; Lepage C; Lièvre A Dig Liver Dis; 2022 Jun; 54(6):747-754. PubMed ID: 35351371 [TBL] [Abstract][Full Text] [Related]
35. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717 [TBL] [Abstract][Full Text] [Related]
36. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638 [TBL] [Abstract][Full Text] [Related]
37. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099 [TBL] [Abstract][Full Text] [Related]
38. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T; Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371 [TBL] [Abstract][Full Text] [Related]
39. Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Mei Y; Shi M; Zhu Z; Yuan H; Yan C; Li C; Feng T; Yan M; Zhang J; Zhu Z Future Oncol; 2022 Jan; 18(2):139-148. PubMed ID: 34877867 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ; Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]